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Abstract
Background: Amongst the extensive literature on immunohistochemical profile of breast cancer, very little is
found on populations exposed to a potential risk factor such as depleted uranium. This study looked at the
immunohistochemical expression of HER-2/neu (c-erbB2) and p53 in different histological types of breast cancer
found in the middle Euphrates region of Iraq, where the population has been exposed to high levels of depleted
uranium.
Findings: The present investigation was performed over a period starting from September 2008 to April 2009.
Formalin-fixed, paraffin-embedded blocks from 70 patients with breast cancer (62 ductal and 8 lobular carcinoma)
were included in this study. A group of 25 patients with fibroadenoma was included as a comparative group, and
20 samples of normal breast tissue sections were used as controls. Labeled streptavidin-biotin (LSAB+) complex
method was employed for immunohistochemical detection of HER-2/neu and p53.
The detection rate of HER-2/neu and p53 immunohistochemical expression were 47.14% and 35.71% respectively
in malignant tumors; expression was negative in the comparative and control groups (p < 0.05).
HER-2/neu immunostaining was significantly associated with histological type, tumor size, nodal involvement, and
recurrence of breast carcinoma (p < 0.05), p53 immunostaining was significantly associated with tumor size, nodal
involvement and recurrence of breast cancer (p < 0.05). There was greater immunoexpression of HER-2/neu in
breast cancer in this population, compared with findings in other populations.
Both biomarkers were positively correlated with each other. Furthermore, all the cases that co-expressed both HER-
2/neu and p53 showed the most unfavorable biopathological profile.
Conclusion: P53 and HER-2/neu over-expression play an important role in pathogenesis of breast carcinoma. The
findings indicate that in regions exposed to high levels of depleted uranium, although p53 and HER-2/neu
overexpression are both high, correlation of their expression with age, grade, tumor size, recurrence and lymph
node involvement is similar to studies that have been conducted on populations not exposed to depleted
uranium. HER-2/neu expression in breast cancer was higher in this population, compared with results on non-
exposed populations.
Introduction
Breast carcinoma constitutes around one quarter of all
cancers, making it the most common cancer in females
[1], it is a heterogeneous disease with high individual
variability as far as response to treatment is concerned
[2]. Despite the increasing incidence rates of breast
cancer, the morbidity and mortality rates are beginning
to fall. This decrease may reflect improvements in meth-
ods of diagnosis and treatment [3]. Several molecular
markers that are important in the clinical aspect of
malignancies especially in breast cancer have been
detected [4]. Biological markers capable of predicting
responsiveness to therapy would be of great help to phy-
sicians aiming to select the most appropriate treatment
for each patient [5]. HER2/neu and p53 (both genes
map to chromosome 17) are known biomarkers of
breast cancer. HER2/neu is a member of the epidermal
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HER2/neu gene results in synthesis of 185kD transmem-
brane protein, whose intracellular domain possesses tyr-
osine kinase activity and through phosphorylation
induction leads to tumor cell proliferation [6]. HER2/
neu amplification or over- expression has been shown
to be associated with higher grades of tumor and poorer
prognosis [6,7]. P53 is involved in regulating cell prolif-
eration, including apoptosis, and in promoting chromo-
somal stability. It has been demonstrated that some
percentage of breast cancers with mutations in p53
tumor suppressor gene are associated with clinical
aggressiveness [8-12]. The prognostic and predictive
value of HER2 and p53 biomarkers has been the subject
of many investigations [10,11], though the significance
of their expression in cancer prognosis requires further
study.
With respect to hormone receptors status (estrogen (ER)
and progesterone (PR)), Breast cancer is considered as a
hormone - dependent cancer. In published literature,
approximately 50% of tumors are ER+ PR+; 25% ER- PR-;
20% ER+ PR- and 5% are ER-PR+ [13,14]. Indeed, the
estrogen receptor (ER) and the progesterone receptor (PR)
have been widely accepted as established parameter in the
management of patients with primary breast cancer along
with HER-2/neu and P53 status as prognostic markers.
Her-2/neu shows over- expression in high grade cancer
and displays lower responsiveness to hormone receptors
modulators. Hormone receptors positivity also correlate
with absence of p53 mutation [15] and inversely with the
presence of epidermal growth factor receptor [16].
On the other hand, Uranium exposure risk has been
assessed in terms of radiation exposure. Human expo-
sure to DU can occur through various routes including
inhalation of DU particles, ingestion of DU-contami-
nated drinking water, soil, food or penetration of the
body by bullets or shrapnel. It has been estimated that
that 371 tones of DU were deposited in Iraqi Soil during
the Desert Storm alone [17]. Recent literature includes
much experimental evidence of adverse effects of DU
including: altered gene expression in vitro [18], DNA
strand breakage [19], carcinogenic mutation of human
bronchial tissue [20] and genomic instability of human
osteoblasts [21,22]. DU also produces increased urinary
mutagenicity using the Ames test in rats [23]. Indeed,
exposure to radiation leads to mutations in components
of signaling pathways that control cell growth. Ulti-
mately, these changes drive tumorigenesis through the
coordinated phosphorylation of proteins, cell-cycle pro-
gression and metabolism, and transcription factors that
regulate the expression of genes involved in these pro-
cesses [24,25]. The mutations that cause cancer is pro-
duced by complex interactions between environmental
and inherited factors. It is unlikely that a single specific
abnormality causes all breast cancer. Defective P53
tumor suppressor gene, could allow abnormal cells to
proliferate, resulting ultimately in cancer. As many as
50% of all human tumors are associated with P53 muta-
tions [26]. HER-2 is encoded by the erbB-2 gene, the
human homologue of the rat proto-oncogen neu [27].
Damage to either type of genes (tumor - suppressor
gene and proto-oncogene) due to exposure to environ-
mental factors (e.g. DU) can results in uncontrolled divi-
sion of cells. This uncontrolled division forms tumors.
The present study is the first to look at the co-expres-
sion of these biomarkers in breast tissue samples from
Iraqi women of the middle Euphrates area where the
population was exposed to high levels of depleted ura-
nium following the Gulf War. The results of this work
are compared to findings on co-expression of these bio-
markers in studies on breast cancer from other parts of
the world, where depleted uranium exposure is not a risk.
Methods
Approval for the study was granted by the Iraqi Ministry
of Higher Education and Scientific Research Ethics
Committee and followed the Tents of Declaration of
Helsinki. The Authors wrote to the patients asking if
they would be willing to donate their tissues for the pro-
ject. Families of individuals were also contacted. The
samples were taken from consenting individuals and
their families.
Seventy specimens of formalin-fixed, paraffin
embedded breast cancer tissue, collected from breast
cancer patients over a period from September 2008 to
April 2009 were included in this study. All cases were
referred to Kufa School of Medicine Teaching Hospital
for histopathological evaluation from different parts of
the middle Euphrates region of Iraq. The age range of
patients was 22 to 70 years, with a mean age of 46.9
years. A group of 25 patients with benign breast
lesions (fibroadenoma) was included as a comparative
group and 20 normal breast tissue sections were
included as controls. Confirmation of histopathological
diagnosis and grading of tumors were carried out after
reviewing all slides before proceeding further to the
immunohistochemical analysis. Tissue sections with a
thickness of 4 μm were taken from the formalin-fixed,
paraffin embedded blocks for immunohistochemistry.
Labeled streptavidin-biotin (LSAB+) method was
employed for immunohistochemical detection of HER-
2/neu and p53 using Polyclonal Rabbit Anti- Human
c-erbB-2 Oncoprotein, Code No. 0485, Dako Denmark
A/S Produktionsvej 42 DK-2600 Glostrup and Mono-
clonal Mouse Anti-Human p53 Protein, Ready-To-Use,
D A K O ,C l o n eD O - 7 ,C o d eN 1 5 8 1 ,I n c .6 3 9 2 ,C A
93013 USA. The intensity of HER-2/neu cell mem-
brane stain was classified into score 0 (completely
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of the membrane in > 10% of the malignant cells),
score 2+ (moderate staining of the partial membrane
in > 10% of the malignant cells) and score 3+ (strong
circumferential staining of the entire membrane creat-
ing a fish-net pattern in > 10% of the malignant cells)
[11]. The intensity of p53 nuclear stain was classified
into score 0 (negative), score 1+ (weak or mild stain-
ing, with 5-10% tumor cells staining positive), score 2+
(moderate staining with less than 25% of tumor cells
staining positive), score 3+ (strong staining, with 25-
50% of tumor cells staining positive) and score 4+
(highly strong staining with over 50% of tumor cells
staining positive) [12]. All biopsies were classified into
three grades: Grade I, Grade II and Grade III, accord-
ing to the modified Bloom Richardson Grading System
[28]. The results were statistically evaluated with a
Chi-squared test (at a significant level of p <0.05) and
correlation-regression analysis (at a significance level
of R = 0.3) using SSPS software.
Results
HER-2/neu and p53 immunoexpressions were positive
in 47.14% and 35.71% of breast cancer cases, respec-
tively, and negative in all sections of the normal and
benign breast tissues. The differences between these
groups were statistically significant (p <0 . 0 5 )( T a b l e1 ) .
HER-2/neu over-expression was detected in 51.61% of
ductal carcinomas cases and in 12.5% of invasive lobular
carcinoma. The difference was statistically significant
(p < 0.05).
As grouped in Table 1, over- expression of HER-2/neu
was detected in only 40.43% of those with pure invasive
ductal carcinomas (Figure 1), in comparison with 77.68%
of invasive ductal carcinoma with an in situ comedo
component (DCIS), in 100% of invasive ductal carcinoma
with overlying Paget’s disease and in 100% of purely
DCIS (Figure 2) and that with overlying Paget’s disease.
The differences were statistically significant (p < 0.05).
HER-2/neu overexpression was detected in 50% of
both grade I and II (well-moderately differentiated
breast cancer) as compared to 46.43% of Grade III
(poorly differentiated breast cancer). Statistically, no sig-
nificant difference exists (p > 0.05). Furthermore, a posi-
tive HER-2/neu overexpression was detected in all
(100%) of the Tis size breast tumors, in 28.57% of T1
size, 34.21% of T2, 68.42% of T3 and in 50% of T4.
T a b l e1s h o w st h a tt h e r ei sah i g hd e t e c t i o nr a t eo f
HER-2 overexpression in recurrent breast cancer in
comparison with primary lesions (84.21% versus 33.33%)
(p < 0.05), and in the presence (positive) or absence
(negative) of axillary lymph nodes (p < 0.05) (65.52%
versus 22.22%), a detection rate showed no correlation
with patients age.
In the present study, p53 immunoexpression was
detected in 37.10% of the ductal carcinomas cases and
in 25% of invasive lobular carcinoma only (Table 1). P53
Immunoexpression was also detected in 38.30% of those
tumors with pure invasive ductal carcinomas (Figure 3),
in 22.22% of invasive ductal carcinoma with an in situ
comedo component (DCIS), in 50% of invasive ductal
carcinoma with overlying Paget’sd i s e a s e ,i n3 3 . 3 3 %f o r
purely DCIS (Figure 4) and in 100% of those with over-
lying Paget’s disease, in all these cases the incidence is
significantly different from that found in control (p <
0.05). On the other hand, p53 immunoexpression was
detected in 14.29% of both grade I and II (well-moder-
ately differentiated breast cancer) as compared to
41.07% of Grade III (poorly differentiated breast cancer).
It is obvious that p53 immunoexpression was highly
correlated with the grade of tumor (R = 0.9) though no
statistical significant difference was found (P > 0.05).
A positive p53 immunoexpression was detected in 50%
of Tis size of tumor, in 28.57% of T1, in 15.79% of T2,
in 73.68% of T3 and in 50% of T4 size of tumor. A
higher detection rates of p53 immunoexpression was
found in recurrent breast cancer patients compared with
the primary lesions (63.16% versus 25.49%) (p < 0.05)
and in the presence (Positive) or absence (negative) of
auxiliary lymph nodes (58.62% versus 25.93%). Again,
there was a high detection rate in both age groups but
no correlation with age was found. Both biomarkers are
positively correlated with each others with respect to
most clinicopathological parameters(R = 0.9). The per-
centage of the cases coexpressing both tumor markers is
18.57% (Table 2). All these cases showed the worst bio-
pathological profile. The cases that co-expressed both
biomarkers were found in 19.35% of ductal carcinoma,
in 21.43% of poorly differentiated (grade III) tumor, in
50% of T4 tumor size, in 43.49% of those with positive
axillary lymph node and in 47.37% of those that showed
recurrence tumors. Furthermore, the co-expression of
both biomarkers was significantly correlated with tumor
grade and decreasing patients age (R > 0.3) (Table 2).
Discussion
Depleted uranium levels were estimated to be around
320-800 tons in the aftermath of the first Gulf war in
1991 with further comparable levels occurring in 2003.
Since the targets were always in heavily populated areas
in the middle and south of Iraq, the extent of population
exposure has been extensive [29]. It has not been possible
to obtain accurate measures of exposure because of offi-
cial restrictions and the current political situation. Whilst
there is plenty of anecdotal evidence for increases in the
incidence of malignancies, infertility and congenital mal-
formations, there is a paucity of studies to investigate
these conditions on Iraqi populations. This has been
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pounded by the destruction of laboratory facilities and
the lack of scientific and medical personnel. This study is
the first to study breast cancer in an Iraqi population that
had been exposed to high levels of depleted uranium and
examine how the immunoexpression of HER-/neu and
p53 compared with tumor grade and size.
In the present investigation the percentage of immu-
noexpression in malignant breast lesions ranges from
12.5% to 100% for HER-2/neu and from 22.22%-100%
for p53. This study has found that HER-2/neu was over-
expressed in 47.14% out of 70 breast cancer cases, a
result that is higher than those reported elsewhere
[30-32]. This may reflect the variant genetic make-up in
Table 1 Immunoexpression of HER-2/neu and p53 in relation to clinicopathological parameters of breast carcinoma
Parameters Total number
of patients
No. %
HER-2
overexpression
P53
immunoexpression
Positive
No. %
Negative
No. %
Positive
No. %
Negative
No. %
Type of breast tissue
Normal 20 (17.39) 0 (0) 20 (100) 0 (0) 20 (100)
Benign (fibroadenoma) 25 (21.74) 0 (0) 25 (100) 0 (0) 25 (100)
Malignant 70 (60.87) 33 (47.14) 37 (52.86) 25 (35.71) 45 (64.29)
P < 0.05 P < 0.05
Histological type
Lobular carcinomas 8 (11.43) 1 (12.50) 7 (87.50) 2 (25) 6 (75)
Ductal carcinomas including: 62 (88.57) 32 (51.61) 30 (48.39) 23 (37.10) 39 (62.90)
P < 0.05 P > 0.05
Pure IDC 47 (67.14) 19 (40.43) 28 (59.57) 18 (38.30) 29 (61.70)
IDC + DCIS 9 (12.86) 7 (77.68) 2 (22.22) 2 (22.22) 7 (77.78)
IDC+ Paget’s 2 (2.86) 2 (100) 0 (0) 1 (50) 1 (50)
DCIS + Paget’s 1 (1.44) 1 (100) 0 (0) 1 (100) 0 (0)
Pure DCIS 3 (4.29) 3 (100) 0 (0) 1 (33.33) 2 (66.67)
P < 0.05 P > 0.05
Tumor grade
Well-moderately differentiated (I and II) 14 (20) 7 (50) 7 (50) 2 (14.29) 12 (85.71)
Poorly differentiated (III) 56 (80) 26 (46.43) 30 (53.57) 23 (41.07) 33 (58.93)
P > 0.05, R > 0.3 P > 0.05, R > 0.3
Tumor size
Tis 4 (5.71) 4 (100) 0 (0) 2 (50) 2 (50)
T1 (≤
2 cm)
7 (10) 2 (28.57) 5 (71.43) 2 (28.57) 5 (71.43)
T2 (2 > -5 cm) 38 (54.29) 13 (34.21) 25 (65.79) 6 (15.79) 32 (84.21)
T3 (> 5 cm) 19 (27.14) 13 (68.42) 6 (31.58) 14 (73.68) 5 (26.32)
T4 (anyT+other) 2 (2.86) 1 (50) 1 (50) 1 (50) 1 (50)
P < 0.05 R < 0.3 P < 0.05 R > 0.3
Axillary lymph nodes1
Negative 27 (48.21) 6 (22.22) 2 (77.78) 7 (25.93) 20 (74.07)
Positive 29 (51.79) 19 (65.52) 10 (34.48) 17 (58.62) 12 (41.38)
P < 0.05 P < 0.05
Age of the patient
< 35 years 19 (27.14) 12 (63.16) 7 (36.84) 8 (42.11) 11 (57.89)
> 35years 51 (72.86) 21 (41.18) 30 (58.82) 17 (33.33) 34 (66.67)
P > 0.05 P > 0.05
Tumor recurrence
Primary 51 (72.86) 17 (33.33) 34 (66.67) 13 (25.49) 38 (74.51)
Recurrent 19 (27.14) 16 (84.21) 3 (15.79) 12 (63.16) 7 (36.84)
P < 0.05 P < 0.05
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mental damaging agents.
Furthermore, previous work that had been carried out
i nt h es a m ea r e as h o w e dr e l a t i v e l yh i g h e rH E R - 2 / n e u
over- expression (67.8%) compared to the present inves-
tigation, though there was no significant difference was
found between the two studies, the differences between
the two can possibly be attributed to either the differ-
ences in the sample sizes, the period of samples collec-
tion or the sensitivity of the kit that had been used [33].
The immunoexpression of HER-2/neu in ductal carci-
nomas was significantly greater than that in infiltrating
lobular carcinomas. The rate of expression of this biolo-
gical marker was similar in both Paget cells and in the
underlying intraductal and/or ductal carcinoma cells.
The current study showed that 100% of pure DCIS
and 77.78% of DCIS with invasive component were
HER2/neu positive. These results are consistent with
previous findings that indicated a role of HER-2/neu in
initiation rather than in progression of ductal carcino-
mas and suggested that this biomarker decreases as indi-
vidual tumor cells evolve from in situ to increasingly
invasive lesions [32]. HER-2/neu overexpression was
seen in all cases which showed either invasive ductal
carcinoma with Paget’s disease or ductal carcinoma in
situ with overlying Paget’s disease components.
The proportions of purely invasive ductal carcinomas,
purely DCIS and DCIS with invasive component that
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Figure 1 Invasive ductal carcinoma, showing strong
membranous staining of Her2/neu, score 2+ (arrowed) (40×).
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Figure 2 In situ ductal carcinoma of comedo type, showing
strong membranous staining of Her2/neu, score 2+ (arrowed)
(10×).
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Figure 3 Invasive ductal carcinoma showing strong nuclear
staining of P53, score 2+ (arrowed) (40×).
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Figure 4 In situ ductal carcinoma showing strong nuclear
staining of P53, score 3+ (arrowed) (20×).
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studies [34]. Paget’s disease showed p53 expression in
50% of cases with an invasive component and in all
cases which had an intra-ductal growth pattern.
Although a positive correlation between detection of
HER-2/neu and p53 biomarkers with the grade of tumor
was observed, no statistically significant difference was
seen between these grades when compared for both bio-
markers. This suggests that as the tumor advances other
biological changes may occur that reduce the requirement
for continued biomarker signaling. It is also possible that,
when gene alterations occur in breast cancer, high prolif-
eration rates are found irrespective of the presence of inva-
sion and that other molecular alterations are involved in
the development of breast cancer [35], Accordingly, the
degree of differentiation does not contribute to the
increase of the expression of both markers, though it may
reflect the possible role of other pathways by which the
Table 2 Coexpression of HER-2/neu and p53 in relation to clinicopathological parameters of breast carcinoma
Parameters Both HER-2/neu and
p53 positive
Only HER-2/neu
positive
Only p53
positive
both HER-2/neu and
p53 negative
Total
Histological type
Ductal Carcinoma 12
(19.35%)
20
(32.25%)
11
(17.45%)
19
(30.65%)
62
(88.57%)
Lobular Carcinoma 1
(12.50%)
0
(0%)
1
(12.50%)
6
(75%)
8
(11.43%)
R > 0.3
Tumor grade
Well-moderately differentiated
(I and II)
1
(7.14%)
6
(42.86%)
1
(7.14%)
6
(42.86%)
2
(2.86%)
Poorly differentiated (III) 12
(21.43%)
14
(25%)
11
(19.64%)
19
(33.93%)
56
(80%)
R < 0.3
Tumor size
Tis 2
(50%)
2
(50%)
0
(0%)
0
(0%)
4
(5.71%)
T1 0
(0%)
2
(28.57%)
2
(28.57%)
3
(42.86%)
7
(10%)
T2 2
(5.26%)
11
(28.94%)
4
(10.53%)
21
(55.27%)
38
(54.29%)
T3 8
(42.12%)
5
(26.31%)
6
(31.57%)
0
(0%)
19
(27.14%)
T4 1
(50%)
0
(0%)
0
(0%)
1
(50%)
2
(2.86%)
R > 0.3
Axillary lymph nodes
Node +ve
breast cancer
10
(34.49%)
9
(31.03%)
7
(24.14%)
3
(10.34%)
29
(51.79%)
Node-ve
breast cancer
2
(7.41%)
4
(14.81%)
5
(18.52%)
16
(59.26%)
27
(48.21%)
R < 0.3
Age of the patient
< 35 years 8
(4211%)
4
(21.05%)
0
(0%)
7
(36.84%)
19
(27.14%)
> 35years 5
(9.81%)
16
(31.37%)
12
(23.53%)
18
(35.29%)
51
(72.86%)
R > -0.3
Tumor recurrence
Primary 4
(7.84%)
13
(25.49%)
9
(17.65%)
25
(49.02%)
51
(72.86%)
Recurrent 9
(47.37%)
7
(36.84%)
3
(15.79%)
0
(0%)
19
(27.14%)
Total 13
(18.57%)
20
(28.57%)
12
(17.14%)
25
(35.71%)
70
(100%)
R > 0.3
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signaling pathways of both HER2/neu and p53 genes.
Thus, introducing a new line of treatment which include a
genetic modulation of the signaling pathway may alter the
prognosis of breast cancer patients which clearly requires
further attention in future research and medical follow up.
The detection rate of p53 increased with size of tumor
and there was a significant difference among the various
tumor sizes (p < 0.05). This observation is consistent with
previous investigations [36-39].
There was a significantly higher HER-2/neu and p53
immunoexpression in recurrent breast cancer patients
compared with the primary lesions (p < 0.05). This is
comparable with findings in previous studies [34-37] as
is the strong correlation between HER-2/neu and p53
co-expression and grade, lymph node and tumor recur-
rence found in this study [40-43]. However, dissenting
results that did not find a correlation between HER-2/
neu and p53 co-expression and other prognostic para-
meter have also been reported [44].
The present work confirms previous findings that
combined alteration in the expression of HER-2/neu
and p53, are linked to accelerated tumor progression
and a poor prognosis [45]. Other studies, however, have
suggested that tumor aggressiveness, associated with ele-
vated expression of either protein, is not increased by
t h ea l t e r a t i o no fas e c o n dp r o t e i ni n v o l v e di nt h es a m e
signal transduction pathway [46].
Conclusion
In conclusion, the positive expression of these biomar-
kers is associated with biologically aggressive tumors
and poor prognostic profile. Although the samples were
taken from an area where the exposure to depleted ura-
nium is a risk, the incidence of co-expression of both
p53 and HER-2/neu markers does not differ from simi-
lar cancer samples in areas that have not been exposed
to depleted uranium, though, the greater immunoex-
pression of Her-2/neu in breast cancer in this popula-
tion with risk for DU exposure, compared with findings
on other populations not at risk, requires further inves-
tigation as it may reflect the possible role of DU in the
induction or acceleration of network signaling between
different Her-2 receptors. New lines of treatment which
includes genetic modulation of the signaling pathway of
both genes should be considered in patients’ medical
follow up. Unfortunately for DU, knowledge of the
exposure time, dose absorbed, route, length of exposure
and its health consequences on the Iraqi population is
still lacking. This is chiefly due to restricted access of
scientists required to conduct such study and should
form the basis for future investigations.
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